This conference report summarizes eight investigational treatments for epilepsy — in preclinical and early clinical development — presented at the EILAT XVIII conference (Madrid, May 2026), covering novel mechanisms including potassium channel modulation, antisense oligonucleotides, MEK inhibition, GABA aminotransferase inhibition, pannexin 1 blockade, filamin A modulation, PDE4B inhibition, and tau dephosphorylation promotion.
Eight agents were reviewed: AUT00206 (Kv3.1/3.2 PAM), ION283 (ASO for Lafora disease), MSCA-7136 (MEK inhibitor for focal/TSC seizures), OV329 (GABA aminotransferase inhibitor), PTI5803/probenecid (pannexin 1 blocker for focal cortical dysplasia), simufilam (filamin A modulator for TSC epilepsy), SN-2000 (PDE4B inhibitor for focal seizures), and sodium selenate (disease-modifying agent for mesial temporal lobe epilepsy); no clinical efficacy or safety outcome data are reported in the abstract.
Full text was inaccessible — only the abstract was available; no quantitative efficacy, safety, or tolerability data are presented; all agents are preclinical or in early clinical stages, limiting clinical applicability.
These agents represent a diverse pipeline of novel mechanisms for drug-resistant and rare epilepsies, but none are yet ready for clinical use — clinicians should monitor their progression in future trials.
Explore related topics
